Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05897099 · ClinicalTrials.gov registry record · NA
Comprehensive HIV and Harm Prevention Via Telehealth
A NA study of HIV Infections, sponsored by University of Miami.
- Recruiting
- Registry status
- NA
- Development phase
- 350
- Enrollment target
- 2
- Study locations
NCT05897099: Recruiting NA study of HIV Infections, sponsored by University of Miami.
NCT05897099 is a NA study of HIV Infections that is actively recruiting participants, run by University of Miami. The registered enrollment target is 350 participants, below the 445-participant average among 542 other HIV Infections trials with a reported enrollment target (21% lower). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05897099, a NA study of HIV Infections, is actively recruiting participants, sponsored by University of Miami.
- RECRUITING
- Registry status
- NA
- Development phase
- 350 participants
- Enrollment target
- 2
- Study locations
Study Summary
The purpose of this study is to test 2 different ways to offer medications to prevent human immunodeficiency virus (HIV), cure hepatitis C virus (HCV) (if applicable) and treat substance use disorder (if desired) in people who inject drugs.
Primary Outcome
Intracellular levels of tenofovir diphosphate (TFV-DP) by DBS or cabotegravir injection in previous 8 weeks or lenacapavir injection in previous 6 months by electronic health record abstraction
Conditions Studied
Interventions
- BEHAVIORAL Comprehensive Tele-harm Reduction
- BEHAVIORAL Off-site Linkage to HIV Prevention
Study Locations (2)
Florida
- IDEA Miami - Miami
- IDEA Syringe Services Program - Miami
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 350 participants |
| Start Date | 2024-10-07 |
| Est. Completion | 2028-05-31 |
| Phase | NA |
What NCT05897099 shows while recruiting
NCT05897099 is an interventional study that assigns participants to a tested intervention. The registered 350 participants enrollment target is mid-sized for trials with a published cap, below the 445-participant average among 542 other HIV Infections trials with a reported enrollment target (21% lower).
The record links to 1 condition, with HIV Infections appearing as the primary indexed condition, and to 2 interventions - of which Comprehensive Tele-harm Reduction is the first listed.
NCT05897099 reports a single indexed study location in Florida.
Frequently Asked Questions
What is clinical trial NCT05897099 about?
NCT05897099 is a clinical study titled "Comprehensive HIV and Harm Prevention Via Telehealth". The purpose of this study is to test 2 different ways to offer medications to prevent human immunodeficiency virus (HIV), cure hepatitis C virus (HCV) (if applicable) and treat substance use disorder (if desired) in people who inject drugs.
What is the current status of trial NCT05897099?
This trial is currently recruiting. It is a NA study. The enrollment target is 350 participants. The study started on 2024-10-07. Estimated completion is 2028-05-31.
What conditions does trial NCT05897099 study?
This clinical trial studies the following conditions: HIV Infections.
What interventions are being tested in trial NCT05897099?
The interventions under investigation include: Comprehensive Tele-harm Reduction (BEHAVIORAL), Off-site Linkage to HIV Prevention (BEHAVIORAL).
Who is sponsoring clinical trial NCT05897099?
This trial is sponsored by University of Miami, which has 721 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05897099 being conducted?
This trial has 2 study locations across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for HIV Infections
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05897099's enrollment target sits among peer trials
350 98th of 542 higher than 443 of 542 other HIV Infections trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other HIV Infections trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
TRAC-ER Intervention to Reduce Risky Alcohol Use and HIV Risk
RECRUITING · NA
-
Community-based Education, Navigation, and Support Intervention for Military Veterans
RECRUITING · NA
-
WiseApp for Spanish Speakers Living With HIV
RECRUITING · NA
-
Substance Checking Outreach and Pre-Exposure Prophylaxis (PrEP) Engagement Study
RECRUITING · NA
-
Food as Medicine for HIV and Diabetes
RECRUITING · NA
-
Screen Smart: Using Digital Health to Improve HIV Screening and Prevention
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00900575 · 350 participants · NA
Cervical Cancer Detection Using Optical Spectroscopy
- NCT01627821 · 350 participants · NA
Evaluation of the Jarvik 2000 Left Ventricular Assist System With Post-Auricular Connector--Destination Therapy Study
- NCT02357654 · 350 participants · Phase 4
GnRH for Luteal Support in IVF/ICSI/FET Cycles
- NCT03997370 · 350 participants · Phase 1
Evaluation of Dosing Procedures of Chemotherapy Treatment (Carboplatin) With the Contrast Agent Iohexol
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI